Detection of EPO gene doping in blood

Publication type:
Journal article
Metadata:
Autoren
  • Elmo WI Neuberger
  • Magdalena Jurkiewicz
  • Dirk A Moser
  • Perikles Simon
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000311436000008&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1002/dta.1347
eISSN
1942-7611
Externe Identifier
  • Clarivate Analytics Document Solution ID: 041XT
  • PubMed Identifier: 22508654
ISSN
1942-7603
Ausgabe der Veröffentlichung
11
Zeitschrift
DRUG TESTING AND ANALYSIS
Schlüsselwörter
  • gene doping
  • gene therapy
  • detection
  • EPO
  • erythropoietin
Paginierung
859 - 869
Datum der Veröffentlichung
2012
Status
Published
Titel
Detection of EPO gene doping in blood
Sub types
  • Review
Ausgabe der Zeitschrift
4

Data source: Web of Science (Lite)

Other metadata sources:
Abstract
<jats:p>Gene doping – or the abuse of gene therapy – will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in <jats:italic>ex vivo</jats:italic> and <jats:italic>in vivo</jats:italic> gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk its health to gain a competitive advantage. This includes the use of technologies that lack safety approval. Sophisticated detection approaches are a prerequisite for prevention of unapproved and uncontrolled use of gene therapy technology. In this review, we present current detection approaches for EPO gene doping, with a focus on blood‐based direct and indirect approaches. Gene doping is detectable in principle, and recent DNA‐based detection strategies enable long‐term detection of transgenic DNA (tDNA) following <jats:italic>in vivo</jats:italic> gene transfer. Copyright © 2012 John Wiley &amp; Sons, Ltd.</jats:p>
Autoren
  • Elmo WI Neuberger
  • Magdalena Jurkiewicz
  • Dirk A Moser
  • Perikles Simon
DOI
10.1002/dta.1347
eISSN
1942-7611
ISSN
1942-7603
Ausgabe der Veröffentlichung
11
Zeitschrift
Drug Testing and Analysis
Sprache
en
Online publication date
2012
Paginierung
859 - 869
Datum der Veröffentlichung
2012
Status
Published
Herausgeber
Wiley
Herausgeber URL
http://dx.doi.org/10.1002/dta.1347
Datum der Datenerfassung
2023
Titel
Detection of <i>EPO</i> gene doping in blood
Ausgabe der Zeitschrift
4

Data source: Crossref

Abstract
Gene doping--or the abuse of gene therapy--will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in ex vivo and in vivo gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk its health to gain a competitive advantage. This includes the use of technologies that lack safety approval. Sophisticated detection approaches are a prerequisite for prevention of unapproved and uncontrolled use of gene therapy technology. In this review, we present current detection approaches for EPO gene doping, with a focus on blood-based direct and indirect approaches. Gene doping is detectable in principle, and recent DNA-based detection strategies enable long-term detection of transgenic DNA (tDNA) following in vivo gene transfer.
Addresses
  • Department of Sports Medicine, Rehabilitation and Disease Prevention, Johannes Gutenberg University Mainz, Mainz, Germany.
Autoren
  • Elmo WI Neuberger
  • Magdalena Jurkiewicz
  • Dirk A Moser
  • Perikles Simon
DOI
10.1002/dta.1347
eISSN
1942-7611
Externe Identifier
  • PubMed Identifier: 22508654
Funding acknowledgements
  • NIGMS NIH HHS: T32 GM008444
Open access
false
ISSN
1942-7603
Ausgabe der Veröffentlichung
11
Zeitschrift
Drug testing and analysis
Schlüsselwörter
  • Animals
  • Humans
  • Erythropoietin
  • DNA
  • Gene Transfer Techniques
  • Substance Abuse Detection
  • Transgenes
  • Doping in Sports
  • Transcriptome
Sprache
eng
Medium
Print-Electronic
Online publication date
2012
Paginierung
859 - 869
Datum der Veröffentlichung
2012
Status
Published
Datum der Datenerfassung
2012
Titel
Detection of EPO gene doping in blood.
Sub types
  • Research Support, Non-U.S. Gov't
  • Review
  • Journal Article
Ausgabe der Zeitschrift
4

Data source: Europe PubMed Central

Abstract
Gene doping--or the abuse of gene therapy--will continue to threaten the sports world. History has shown that progress in medical research is likely to be abused in order to enhance human performance. In this review, we critically discuss the progress and the risks associated with the field of erythropoietin (EPO) gene therapy and its applicability to EPO gene doping. We present typical vector systems that are employed in ex vivo and in vivo gene therapy trials. Due to associated risks, gene doping is not a feasible alternative to conventional EPO or blood doping at this time. Nevertheless, it is well described that about half of the elite athlete population is in principle willing to risk its health to gain a competitive advantage. This includes the use of technologies that lack safety approval. Sophisticated detection approaches are a prerequisite for prevention of unapproved and uncontrolled use of gene therapy technology. In this review, we present current detection approaches for EPO gene doping, with a focus on blood-based direct and indirect approaches. Gene doping is detectable in principle, and recent DNA-based detection strategies enable long-term detection of transgenic DNA (tDNA) following in vivo gene transfer.
Date of acceptance
2012
Autoren
  • Elmo WI Neuberger
  • Magdalena Jurkiewicz
  • Dirk A Moser
  • Perikles Simon
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/22508654
DOI
10.1002/dta.1347
eISSN
1942-7611
Funding acknowledgements
  • NIGMS NIH HHS: T32 GM008444
Ausgabe der Veröffentlichung
11
Zeitschrift
Drug Test Anal
Schlüsselwörter
  • Animals
  • DNA
  • Doping in Sports
  • Erythropoietin
  • Gene Transfer Techniques
  • Humans
  • Substance Abuse Detection
  • Transcriptome
  • Transgenes
Sprache
eng
Country
England
Paginierung
859 - 869
Datum der Veröffentlichung
2012
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2013
Titel
Detection of EPO gene doping in blood.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review
Ausgabe der Zeitschrift
4

Data source: PubMed

Beziehungen:
Property of

Tools